Literature DB >> 18415850

Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis.

Eric Milefchik1, Mary Ann Leal, Richard Haubrich, Samuel A Bozzette, Jeremiah G Tilles, John M Leedom, J Allen McCutchan, Robert A Larsen.   

Abstract

An all oral treatment for cryptococcal meningitis is attractive, particularly where amphotericin B use is impractical. Both fluconazole and flucytosine are available in oral formulations and have activity against Cryptococcus neoformans. We conducted a prospective phase II dose escalation study employing doses of fluconazole ranging from 800 to 2000 mg daily for 10 weeks used alone or combined with flucytosine at 100 mg/kg per day for the first 4 weeks. We found that increasing doses of fluconazole were associated with an increase in survival and a decrease in the time to conversion of the cerebrospinal fluid from culture positive to culture negative. Addition of flucytosine to fluconazole improved outcomes in each dosing cohort. High doses of fluconazole alone or combined with flucytosine were well tolerated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18415850     DOI: 10.1080/13693780701851695

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  31 in total

Review 1.  Management of cryptococcal meningitis in sub-saharan Africa.

Authors:  Arthur Jackson; Mina C Hosseinipour
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

2.  Population Pharmacokinetic Modeling to Describe the Total Plasma and Free Brain Levels of Fluconazole in Healthy and Cryptococcus neoformans Infected Rats: How Does the Infection Impact the Drug's Levels on Biophase?

Authors:  Izabel Almeida Alves; Keli Jaqueline Staudt; Fernando Olinto Carreño; Graziela de Araujo Lock; Carolina de Miranda Silva; Stela Maris Kuze Rates; Teresa Dalla Costa; Bibiana Verlindo De Araujo
Journal:  Pharm Res       Date:  2018-04-27       Impact factor: 4.200

Review 3.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

4.  Heterocycle Thiazole Compounds Exhibit Antifungal Activity through Increase in the Production of Reactive Oxygen Species in the Cryptococcus neoformans-Cryptococcus gattii Species Complex.

Authors:  Nívea Pereira de Sá; Caroline Miranda de Lima; Cleudiomar Inácio Lino; Paulo Jorge Sanches Barbeira; Ludmila de Matos Baltazar; Daniel Assis Santos; Renata Barbosa de Oliveira; Eleftherios Mylonakis; Beth Burgwyn Fuchs; Susana Johann
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

5.  Cryptococcal meningitis: current approaches to management in patients with and without AIDS.

Authors:  Kyle D Brizendine; Peter G Pappas
Journal:  Curr Infect Dis Rep       Date:  2010-07       Impact factor: 3.725

6.  Cryptococcus neoformans: the model organism for yeast antifungal drug susceptibility testing.

Authors:  Madeline Bauer; Ann M Thomas; Robert A Larsen
Journal:  Mycopathologia       Date:  2012-02-10       Impact factor: 2.574

Review 7.  Asymptomatic cryptococcemia in resource-limited settings.

Authors:  Ana-Claire Meyer; Mark Jacobson
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

8.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

9.  Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine.

Authors:  Manjunath P Pai; Hollie Bruce; Linda A Felton
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

10.  A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis.

Authors:  Arthur T Jackson; Jesse C Nussbaum; Jacob Phulusa; Dan Namarika; Maria Chikasema; Creto Kanyemba; Joseph N Jarvis; Shabbar Jaffar; Mina C Hosseinipour; Charles van der Horst; Thomas S Harrison
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.